SCHEMBL7811212

SCHEMBL7811212

c1cncc(C2c3ccccc3CCc3ccccc32)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 4/20 0.60
▸ CYP19A1 P11511 3/20 0.60
▸ CYP2A6 P11509 1/20 0.49
▸ LMNA P02545 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ CHRNB2 P17787 3/20 0.44
▸ CHRNA4 P43681 2/20 0.44
▸ PLAU P00749 1/20 0.43
▸ RET P07949 1/20 0.43
▸ HTR2A P28223 1/20 0.43
▸ RECQL P46063 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CHRNA7 P36544 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11629644 0.79 CYP2A6 (0.48) CYP11B2CYP19A1CYP2A6HPGDCHRNB2
SCHEMBL23848531 0.79 CYP3A4 (0.55) CYP11B2CYP19A1CYP2A6CHRNB2CHRNA4
SCHEMBL1143328 0.78 GAA (0.59) CYP11B2LMNATP53GAAHPGD
SCHEMBL26785980 0.78 CYP11B2 (0.59) CYP11B2CYP19A1CYP2A6CHRNB2CHRNA4
SCHEMBL30707979 0.77 RECQL (0.69) CYP11B2CYP19A1CYP2A6LMNATP53
SCHEMBL3893524 0.77 RECQL (0.69) CYP11B2CYP19A1CYP2A6LMNATP53
SCHEMBL11629050 0.75 CYP2A6 (0.44) CYP11B2CYP19A1CYP2A6GAAHPGD
SCHEMBL23125588 0.74 CYP2A6 (0.47) CYP11B2CYP19A1CYP2A6LMNATP53
SCHEMBL25652335 0.74 CYP11B2 (0.42) CYP11B2CYP19A1CYP2A6LMNACHRNB2
SCHEMBL28665806 0.73 CYP2A6 (0.51) CYP11B2CYP19A1CYP2A6LMNACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 — — US disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 — — US disclosed
WO-2021188949-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2021-09-23 — — WO disclosed
EP-0733043-B1 TRICYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING CORP (US) 2001-06-20 — — EP disclosed
EP-0733043-A1 TRICYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING CORPORATION (US) 1996-09-25 — — EP disclosed
US-5464840-A Pharmaceuticals to inhibit tumor necrosis factor-alpha and to treat septic shock, inflammation and allergic disease SCHERING CORPORATION (US) 1995-11-07 — — US disclosed
WO-1995015949-A1 TRICYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING CORPORATION (US) 1995-06-15 — — WO disclosed
US-4116665-A Method of regulating the growth of aquatic weeds with pyridine derivatives ELI LILLY AND COMPANY (US) 1978-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 CYP11B2 2106/4885CYP19A1 1981/4885CYP2A6 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback